Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses.
Standard
Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. / Sobottka, Ingo; Wegscheider, Karl; Balzer, Oliver; Böger, Rainer; Hallier, Olaf; Giersdorf, Ina; Streichert, Thomas; Haddad, Munif; Platzer, Ursula; Cachovan, Georg.
in: ANTIMICROB AGENTS CH, Jahrgang 56, Nr. 5, 5, 2012, S. 2565-2569.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses.
AU - Sobottka, Ingo
AU - Wegscheider, Karl
AU - Balzer, Oliver
AU - Böger, Rainer
AU - Hallier, Olaf
AU - Giersdorf, Ina
AU - Streichert, Thomas
AU - Haddad, Munif
AU - Platzer, Ursula
AU - Cachovan, Georg
PY - 2012
Y1 - 2012
N2 - The objective of this study was to identify the oral pathogens found in odontogenic infections, to determine their susceptibilities to amoxicillin-clavulanic acid (AMC), clindamycin (CLI), doxycycline (DOX), levofloxacin (LVX), moxifloxacin (MXF), and penicillin (PEN), and to search for associations between specific pathogens and types of infection. Swabs from patients enrolled in a randomized, double-blind phase II trial comparing MXF with CLI for the treatment of odontogenic abscesses or inflammatory infiltrates were cultured on media for aerobes and anaerobes. All bacterial isolates were identified at the species level. Overall, 205 isolates were cultured from 71 patients: 77 viridans group streptococci, 56 Prevotella spp., 19 Neisseria spp., 17 Streptococcus anginosus group isolates and hemolytic streptococci, 15 other anaerobes, and 21 other bacteria. Ninety-eight percent of pathogens were susceptible to MXF, 96% to AMC, 85% to LVX, 67% to PEN, 60% to CLI, and 50% to DOX. S. anginosus group and hemolytic streptococci were found significantly more frequently (P = 0.04) in patients with abscesses (12/95) than in patients with infiltrates (5/110). In four patients with infiltrates who failed to respond to CLI therapy, three isolates of the Streptococcus mitis group and four Neisseria spp. resistant to CLI were found. In this study, S. anginosus group and hemolytic streptococci were clearly associated with odontogenic abscesses. Our analysis suggests that viridans group streptococci and Neisseria spp. play a decisive role in the etiology of odontogenic infiltrates. The high in vitro activity of MXF against odontogenic bacteria corresponds well to its clinical results in the treatment of odontogenic abscesses and infiltrates.
AB - The objective of this study was to identify the oral pathogens found in odontogenic infections, to determine their susceptibilities to amoxicillin-clavulanic acid (AMC), clindamycin (CLI), doxycycline (DOX), levofloxacin (LVX), moxifloxacin (MXF), and penicillin (PEN), and to search for associations between specific pathogens and types of infection. Swabs from patients enrolled in a randomized, double-blind phase II trial comparing MXF with CLI for the treatment of odontogenic abscesses or inflammatory infiltrates were cultured on media for aerobes and anaerobes. All bacterial isolates were identified at the species level. Overall, 205 isolates were cultured from 71 patients: 77 viridans group streptococci, 56 Prevotella spp., 19 Neisseria spp., 17 Streptococcus anginosus group isolates and hemolytic streptococci, 15 other anaerobes, and 21 other bacteria. Ninety-eight percent of pathogens were susceptible to MXF, 96% to AMC, 85% to LVX, 67% to PEN, 60% to CLI, and 50% to DOX. S. anginosus group and hemolytic streptococci were found significantly more frequently (P = 0.04) in patients with abscesses (12/95) than in patients with infiltrates (5/110). In four patients with infiltrates who failed to respond to CLI therapy, three isolates of the Streptococcus mitis group and four Neisseria spp. resistant to CLI were found. In this study, S. anginosus group and hemolytic streptococci were clearly associated with odontogenic abscesses. Our analysis suggests that viridans group streptococci and Neisseria spp. play a decisive role in the etiology of odontogenic infiltrates. The high in vitro activity of MXF against odontogenic bacteria corresponds well to its clinical results in the treatment of odontogenic abscesses and infiltrates.
KW - Germany
KW - Humans
KW - Male
KW - Female
KW - Prospective Studies
KW - Double-Blind Method
KW - Culture Media
KW - Microbial Sensitivity Tests
KW - Outpatients
KW - Amoxicillin-Potassium Clavulanate Combination/administration & dosage/therapeutic use
KW - Anti-Bacterial Agents/administration & dosage/therapeutic use
KW - Aza Compounds/administration & dosage/therapeutic use
KW - Bacteria, Aerobic/drug effects/growth & development
KW - Bacteria, Anaerobic/drug effects/growth & development
KW - Bacterial Infections/drug therapy/microbiology
KW - Clindamycin/administration & dosage/therapeutic use
KW - Penicillins/administration & dosage/therapeutic use
KW - Periodontal Abscess/drug therapy/microbiology
KW - Quinolines/administration & dosage/therapeutic use
KW - Germany
KW - Humans
KW - Male
KW - Female
KW - Prospective Studies
KW - Double-Blind Method
KW - Culture Media
KW - Microbial Sensitivity Tests
KW - Outpatients
KW - Amoxicillin-Potassium Clavulanate Combination/administration & dosage/therapeutic use
KW - Anti-Bacterial Agents/administration & dosage/therapeutic use
KW - Aza Compounds/administration & dosage/therapeutic use
KW - Bacteria, Aerobic/drug effects/growth & development
KW - Bacteria, Anaerobic/drug effects/growth & development
KW - Bacterial Infections/drug therapy/microbiology
KW - Clindamycin/administration & dosage/therapeutic use
KW - Penicillins/administration & dosage/therapeutic use
KW - Periodontal Abscess/drug therapy/microbiology
KW - Quinolines/administration & dosage/therapeutic use
M3 - SCORING: Journal article
VL - 56
SP - 2565
EP - 2569
JO - ANTIMICROB AGENTS CH
JF - ANTIMICROB AGENTS CH
SN - 0066-4804
IS - 5
M1 - 5
ER -